Vancomycin

Researchers tested two core Infectious Diseases Society of America-recommended antimicrobial stewardship interventions at four community hospitals in North Carolina and found that one — post-prescription audit and review by a pharmacist after 72 hours of therapy — was feasible in facilities with limited resources and little to no antimicrobial stewardship expertise.

SAN DIEGO – Non-alcoholic steatohepatitis-related cirrhosis may be an independent risk factor for recurrent Clostridium difficile infections, according to findings presented at Digestive Disease Week.

NEW YORK — Infection eradication and limited stem migration occurred at 2-year minimum follow-up in patients who underwent staged total hip arthroplasty revision due to infection using a femoral impaction bone grafting technique. The results were similar to those seen with implantation of primary cemented taper-slip prostheses, according to a presenter at the Musculoskeletal Infection Society Annual Open Scientific Meeting.

Whole-genome sequencing, or WGS, surveillance identified an outbreak of vancomycin-resistant Enterococcus faecium infections that was linked to nonsterile preparation of injectable contrast medium for interventional radiology procedures, researchers reported in Clinical Infectious Diseases.

An assessment of hemodialysis facilities in Philadelphia County revealed that almost 60% of new outpatient intravenous antimicrobial starts last year were inappropriate, researchers reported.

A case report recently published in the Journal of the Pediatric Infectious Diseases Society highlighted the first pediatric case of Enterococcus hirae in the United States, and the presentation was a catheter-associated bloodstream infection.

SAN FRANCISCO — Cannabidiol, or CBD, showed surprising effectiveness against gram-positive bacteria in vitro, including some that were resistant to vancomycin and daptomycin, according to research presented at ASM Microbe.

In this guest commentary, Dale N. Gerding, MD, professor of medicine at Loyola University Chicago Stritch School of Medicine, discusses several presentations at ICAAC 2015 that focused on new approaches to the treatment of Clostridium difficile infection and recurrence and the need for more effective C. difficile management strategies.

WASHINGTON, D.C. — Patients reported that a new patient-reported outcome assessment tool developed based on the FDA PRO Guidance for Industry was easy to understand and relevant to their experience of Clostridium difficile-related diarrhea symptoms, according to data presented at ICAAC 2014.

WASHINGTON, D.C. — Semi-synthetic thiopeptide LFF571 was non-inferior to vancomycin and well-tolerated for treatment of moderate primary Clostridium difficile infection or first recurrence, according to clinical trial data presented at ICAAC 2014.